KalVista Pharmaceuticals (KALV) – Investment Analysts’ Recent Ratings Updates

A number of firms have modified their ratings and price targets on shares of KalVista Pharmaceuticals (NASDAQ: KALV) recently:

• 3/26/2025 – KalVista Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
• 3/26/2025 – KalVista Pharmaceuticals had its “buy” rating reaffirmed by analysts at Jones Trading. They now have a $30.00 price target on the stock.
• 3/14/2025 – KalVista Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
• 3/13/2025 – KalVista Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
• 1/31/2025 – KalVista Pharmaceuticals was upgraded by analysts at Citizens Jmp to a “strong-buy” rating.
• 1/31/2025 – KalVista Pharmaceuticals is now covered by analysts at JMP Securities. They set an “outperform” rating and a $19.00 price target on the stock.

KalVista Pharmaceuticals Stock Up 2.2 %

KALV stock opened at $12.34 on Friday. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $15.50. The stock has a market capitalization of $613.50 million, a price-to-earnings ratio of -3.39 and a beta of 0.76. The firm’s fifty day simple moving average is $10.49 and its two-hundred day simple moving average is $10.26.

Insider Buying and Selling

In other news, major shareholder Venrock Healthcare Capital Par bought 14,562 shares of the stock in a transaction on Monday, February 3rd. The stock was acquired at an average cost of $9.22 per share, for a total transaction of $134,261.64. Following the acquisition, the insider now owns 5,012,796 shares of the company’s stock, valued at $46,217,979.12. This represents a 0.29 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Benjamin L. Palleiko sold 5,104 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total value of $50,121.28. Following the transaction, the chief executive officer now owns 278,855 shares in the company, valued at approximately $2,738,356.10. This represents a 1.80 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders acquired 236,055 shares of company stock valued at $2,162,146 and sold 17,292 shares valued at $184,625. 10.50% of the stock is owned by corporate insiders.

Institutional Trading of KalVista Pharmaceuticals

A number of hedge funds have recently bought and sold shares of KALV. Aquatic Capital Management LLC purchased a new position in shares of KalVista Pharmaceuticals in the 4th quarter worth approximately $44,000. Tower Research Capital LLC TRC increased its stake in KalVista Pharmaceuticals by 666.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 5,502 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of KalVista Pharmaceuticals by 22.5% in the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock worth $69,000 after buying an additional 1,494 shares during the last quarter. Martin Worley Group acquired a new stake in shares of KalVista Pharmaceuticals during the fourth quarter worth $86,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of KalVista Pharmaceuticals by 24.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock valued at $87,000 after buying an additional 2,043 shares during the last quarter.

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).